CN115770246B - 卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用 - Google Patents
卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用 Download PDFInfo
- Publication number
- CN115770246B CN115770246B CN202211104669.6A CN202211104669A CN115770246B CN 115770246 B CN115770246 B CN 115770246B CN 202211104669 A CN202211104669 A CN 202211104669A CN 115770246 B CN115770246 B CN 115770246B
- Authority
- CN
- China
- Prior art keywords
- carmofur
- pharmaceutically acceptable
- coronavirus
- acid
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 229960003261 carmofur Drugs 0.000 title claims abstract description 52
- 150000003839 salts Chemical class 0.000 title claims abstract description 37
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 241001678559 COVID-19 virus Species 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 abstract description 44
- 101800000535 3C-like proteinase Proteins 0.000 abstract description 16
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000004176 Alphacoronavirus Species 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 6
- 241000711450 Infectious bronchitis virus Species 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000008904 Betacoronavirus Species 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 241000315672 SARS coronavirus Species 0.000 description 5
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical class FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 241001109669 Human coronavirus HKU1 Species 0.000 description 4
- 241000482741 Human coronavirus NL63 Species 0.000 description 4
- 241001428935 Human coronavirus OC43 Species 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000711467 Human coronavirus 229E Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001292005 Nidovirales Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101710153041 Replicase polyprotein 1a Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 244000306301 Caesalpinia sappan Species 0.000 description 2
- 235000015162 Caesalpinia sappan Nutrition 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241001461743 Deltacoronavirus Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000008920 Gammacoronavirus Species 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241001361508 Porcine deltacoronavirus Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 101710151619 Replicase polyprotein 1ab Proteins 0.000 description 2
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 229960004157 rabeprazole Drugs 0.000 description 2
- KRCQSTCYZUOBHN-UHFFFAOYSA-N rabeprazole sodium Chemical compound [Na+].COCCCOC1=CC=NC(CS(=O)C=2[N-]C3=CC=CC=C3N=2)=C1C KRCQSTCYZUOBHN-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KEQHJBNSCLWCAE-UHFFFAOYSA-N thymoquinone Chemical compound CC(C)C1=CC(=O)C(C)=CC1=O KEQHJBNSCLWCAE-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NYEPHMYJRNWPLA-UHFFFAOYSA-N (6-amino-2-ethoxyacridin-9-yl)azanium;2-hydroxypropanoate;hydrate Chemical compound O.CC(O)C([O-])=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3[NH+]=C21 NYEPHMYJRNWPLA-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 150000004057 1,4-benzoquinones Chemical class 0.000 description 1
- BPBPYQWMFCTCNG-UHFFFAOYSA-N 2-(butan-2-yldisulfanyl)-1H-imidazole Chemical compound CCC(C)SSC1=NC=CN1 BPBPYQWMFCTCNG-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- DLYVTEULDNMQAR-SRNOMOOLSA-N Cholic Acid Methyl Ester Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCC(=O)OC)[C@@]2(C)[C@@H](O)C1 DLYVTEULDNMQAR-SRNOMOOLSA-N 0.000 description 1
- 229920002786 Corilagin Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 241001533413 Deltavirus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 150000001621 bismuth Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- UWHUTZOCTZJUKC-JKSUJKDBSA-N brazilin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C=C1OC2 UWHUTZOCTZJUKC-JKSUJKDBSA-N 0.000 description 1
- UWHUTZOCTZJUKC-CVEARBPZSA-N brazilin Natural products C12=CC(O)=C(O)C=C2C[C@@]2(O)[C@@H]1C1=CC=C(O)C=C1OC2 UWHUTZOCTZJUKC-CVEARBPZSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- TUSDEZXZIZRFGC-XIGLUPEJSA-N corilagin Chemical compound O([C@H]1[C@H](O)[C@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@@H](O1)[C@H]2O)C(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-XIGLUPEJSA-N 0.000 description 1
- CPWYQGWOJMNXGJ-UHFFFAOYSA-N corilagin Natural products OC1C2COC(=O)c3c(O)c(O)c(O)c(O)c3c4c(O)c(O)c(O)c(O)c4C(=O)OC1C(O)C(OC(=O)c5cc(O)c(O)c(O)c5)O2 CPWYQGWOJMNXGJ-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 229960002377 dixanthogen Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- -1 patches Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- ZQGDDMFDBZPGCD-UHFFFAOYSA-N sodium 2-[(4-methoxy-3-methylpyridin-2-yl)methylsulfinyl]-5-pyrrol-1-ylbenzimidazol-3-ide Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(C=C3N=2)N2C=CC=C2)=C1C ZQGDDMFDBZPGCD-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XQDCKJKKMFWXGB-UHFFFAOYSA-N wedelolactone Chemical compound O1C2=CC(O)=C(O)C=C2C2=C1C1=C(O)C=C(OC)C=C1OC2=O XQDCKJKKMFWXGB-UHFFFAOYSA-N 0.000 description 1
- RFQPHWCAHNTCDX-UHFFFAOYSA-N wedelolactone Natural products COc1cc(O)cc2OC(=O)c3c(oc4cc(O)c(O)cc34)c12 RFQPHWCAHNTCDX-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用。卡莫氟在制备治疗和/或预防冠状病毒引发的疾病的药物中的应用。本发明通过体外酶活实验发现卡莫氟可以很好地抑制冠状病毒中的主蛋白酶的活性,填补了现有技术缺乏治疗冠状病毒引发的疾病的不足。
Description
本专利申请为申请号为:CN202110219570.X,申请日为2021年02月26日,发明名称为《多酚类物质在抗冠状病毒中的应用》的分案申请。
技术领域
本发明属于生物医药技术领域,涉及卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用。
背景技术
冠状病毒是一类与人畜密切相关的病毒。冠状病毒HCoV-229E和HCoV-OC43会引起普通感冒(van der Hoek,L.,Pyrc,K.,Jebbink,M.et al.Identification of a newhuman coronavirus.Nat Med 2004,10,368–373)。2004年鉴定出的HCoV-NL63 同样能引起类似感冒的呼吸道疾病(van der Hoek,L.,Pyrc,K.,Jebbink,M.et al. Identificationof a new human coronavirus.Nat Med 2004,10,368–373)。人冠状病毒HKU1 株(HCo V-HKU1)属于β-冠状病毒,于2005年由香港大学研究人员发现,该病毒引起上呼吸道感染。最近流行的SARS-CoV-2病毒会引发COVID-19,临床表现为发烧,干咳和呼吸困难,重症会造成死亡(Jeannette Guarner,MD,Three Emerging Coronaviruses in Two Decades:TheStory of SARS,MERS,and Now COVID-19,American Journal of Clinical Pathology,,aqaa029)。
冠状病毒对于畜牧业影响巨大:猪流行性腹泻病毒(PEDV)可引起猪流行性腹泻(Pocine Epidemic Diarrhea,PED),肠胃炎病毒(TGEV)可引起猪传染性胃肠炎(TGE),猪丁型冠状病毒(Porcine delta coronavirus,PDCoV,也叫猪德尔塔病毒)可引起5-15日龄哺乳仔猪腹泻和呕吐,迅速脱水,衰竭而亡,给养猪业带来巨大的损失(Akimkin V,Beer M,Blome S,et al.New Chimeric Porcine Coronavirus in Swine Feces,Germany,2012.Emerg Infect Dis.2016,22(7):1314–1315)。猫传染性腹膜炎病毒(FIPV)可引起的猫科动物的致死性疾病:猫传染性腹膜炎(FIP)。禽传染性支气管炎病毒(IBV)感染禽类,引起鸡传染性支气管炎,是一种分布广泛的家禽疾病,对家禽业造成了巨大的经济影响。
冠状病毒在系统分类上属套式病毒目(Nidovirales)冠状病毒科(Coronaviridae)冠状病毒亚科(Orthocoronavirinae),日前SARS-CoV-2冠状病毒基因组序列已经公布,该序列与SARS-Cov的核苷酸相似度约为90%,蛋白质序列与SARS-CoV有约80%的序列相似性。冠状病毒的基因组为单股正链RNA,长度约28kb,主要编码病毒包装所需的结构蛋白以及与复制转录相关的非结构蛋白。开发治疗冠状病毒相关疾病的药物和疫苗主要针对上述两类蛋白。病毒基因组的三分之二的基因主要编码非结构蛋白。病毒编码了两种多聚酶蛋白pp1a和pp1ab,用于参与病毒的复制过程。pp1a和pp1ab通过两种由病毒编码的木瓜蛋白酶和主蛋白酶(main protease)可以将其切割成16个非结构蛋白nsp1-16,只有当这些功能亚基被病毒编码的蛋白酶切割成独立的蛋白单元,病毒才能完成正常的转录、复制功能,进而组装成复制转录复合物,完成病毒的复制和转录。其中,木瓜蛋白酶有3个酶切位点;主蛋白酶在pp1a和pp1ab上存在11个酶切位点。可见主蛋白酶在病毒的转录、复制过程中发挥关键的调节作用,因此成为研究的焦点(Ziebuhr,J.; Snijder,E.J.;Gorbalenya,A.E.Virus-encoded proteinases and proteolytic processing in theNidovirales.J Gen Virol 2000,81,853-79.;Ziebuhr,J.Molecular biology of severeacute respiratory syndrome coronavirus.Curr Opin Microbiol 2004,7,412-9.)。由于主蛋白酶对冠状病毒扩增复制的重要性,因此寻找针对主蛋白酶催化位点专一性强、安全性高的抑制剂对于药物开发显得尤其重要。
卡莫氟(Carmofur,分子式为C11H16FN3O3;CAS号:61422-45-5)是氟尿嘧啶的衍生物,是一种抗肿瘤药,口服后从肠道迅速吸收,在体内缓缓释出氟尿嘧啶,借氟尿嘧啶的抗代谢作用而发挥抗肿瘤作用。卡莫氟口服后有效血药浓度较氟尿嘧啶静注长久。抗瘤谱广,治疗指数高,对多种实验肿瘤有较好的抗肿瘤作用。临床上对胃癌、结直肠癌及乳腺癌有一定疗效,尤以结直肠癌的有效率较为突出(KAMIKAMA KANEHITO; KIKUCHIMASAHIKO.STABLE CARMOFUR-BETA-CYCLODEXTRIN CLATHRATE COMPOUND[P].;JPS60185772,1985-09-21.)。
现有技术中尚无卡莫氟可用于治疗冠状病毒引发的相关疾病。
发明内容
本发明所要解决的技术问题是,针对现有技术中尚无有效抑制冠状病毒的药物,本发明提供卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用,具体涉及卡莫氟或其药学上可接受的盐在制备抑制冠状病毒的药物中的应用。
本发明主要通过以下技术方案解决上述技术问题。本发明提供卡莫氟(CAS号:61422-45-5)或其药学上可接受的盐在制备治疗和/或预防冠状病毒引发的疾病的药物中的应用。
卡莫氟(CAS号:61422-45-5)或其药学上可接受的盐在制备治疗和/或预防新型冠状病毒引发的疾病的药物中的应用。
本发明还提供卡莫氟或其药学上可接受的盐在制备抑制冠状病毒的药物中的应用。
较佳地,所述的疾病为哺乳动物所患疾病或者禽类所患疾病。
较佳地,所述的哺乳动物包括人、猪和猫。
所述的疾病或病症可包括:感冒、类似感冒的呼吸道疾病、中东呼吸综合征、发烧、干咳或呼吸困难;以及猪所患的肠炎、腹泻、呕吐或脱水。
本发明所述的冠状病毒,其定义为本领域熟知,在系统分类上属套式病毒目(Nidovirales)冠状病毒科(Coronaviridae)冠状病毒亚科(Orthocoronavirinae)。冠状病毒是具有囊膜(envelope)、基因组为单股正链的RNA病毒,是自然界广泛存在的一大类病毒。
本发明的目的是提供冠状病毒感染引起的疾病的潜在治疗方案。本发明所述的冠状病毒较佳地属于正冠状病毒亚科(Orthocoronavirinae),更佳地属于Alpha冠状病毒属、Beta冠状病毒属、Gamma冠状病毒属或者Delta冠状病毒属。
在本发明一较佳实施例中,卡莫氟或其药学上可接受的盐除可用于治疗SARS-CoV- 2(Beta冠状病毒属)引发的疾病以外,还应可治疗其他冠状病毒SARS-CoV(Beta冠状病毒属)和MERS-CoV等引起的重大传染病,亦可作为普通感冒药,治疗HCoV-HKU1 (Humancoronavirus HKU1;Beta冠状病毒属)、HCoV-NL63(Human coronavirus NL63; Alpha冠状病毒属)、HCoV-OC43(Human coronavirus OC43)以及HCoV-229E(Human coronavirus 22E;Alpha冠状病毒属)等冠状病毒引起的疾病;还可作为兽药,治疗猪传染性胃肠炎病毒(Transmissible gastroenteritis virus,TGEV;Alpha冠状病毒属)、猪流行性腹泻病毒(Porcine epidemic diarrhea virus,PEDV;Alpha冠状病毒属)、猪丁型冠状病毒(Porcinedelta coronavirus,PDCoV;Delta冠状病毒属)、猫传染性腹膜炎病毒(Feline infectiousperitonitis virus,FIPV;Alpha冠状病毒属)、禽传染性支气管炎病毒(Infectiousbronchitis virus,IBV;Gamma冠状病毒属)等动物疾病。
因此,本发明所述冠状病毒的较佳地选自SARS-CoV-2、SARS-CoV、MERS-CoV、HCoV-HKU1、HCoV-NL63、HCoV-OC43、HCoV-229E、TGEV、PEDV、PDCoV、FIPV 或者IBV。
在某一方案中,所述卡莫氟(CAS号:61422-45-5)或其药学上可接受的盐在制备抑制新型冠状病毒的药物中的应用。
在某一方案中,本发明的所述卡莫氟或其药学上可接受的盐以包含其的药物组合物的形式存在;较佳地,所述药物组合物以本发明所述卡莫氟和/或其药学上可接受的盐作为所述药物组合物的唯一活性成份;和/或,所述药物组合物还包含药学上可接受的载体,例如药学上可接受的药用辅料。
在某一方案中,本发明的所述卡莫氟或其药学上可接受的盐以包含其的套装药盒的形式存在,所述套装药盒还包括治疗与冠状病毒相关的疾病的药物和/或治疗其他病毒引起的疾病的药物。
本发明中,所述卡莫氟或其药学上可接受的盐还可以与其他一种或多种药物活性成分联用。所述其他一种或多种药物活性成分包括:多酚类物质、质子泵抑制剂、对苯醌及其衍生物、苏木的活性成分、TDZD-8、硫柳汞、紫草素、Tideglusib、原黄素、雷贝拉唑钠、PX-12、Dixanthogen、胆酸甲酯、柯里拉京、二氢杨梅素、氯胺T、汞溴红、没食子儿茶素、秦皮素、甲异靛、乳酸乙吖啶一水合物以及南索拉唑中的一种或多种。
所述的苏木的活性成分较佳地选自苏木精、原苏木素B或者巴西木素。
所述的对苯醌衍生物较佳地选自百里香醌或者1,4-萘醌。
所述的质子泵抑制剂较佳地选自雷贝拉唑钠、艾普拉唑钠或者埃索美拉唑镁。
所述的多酚类物质较佳地选自蟛蜞菊内酯、表没食子儿茶素没食子酸酯、甲基儿茶酚、茶多酚或者迷迭香酸。
本发明中涉及的以本发明所述卡莫氟或其药学上可接受的盐作为活性成份的药物组合物,均可根据本领域公知的方法制备。可通过将本发明所述卡莫氟或其药学上可接受的盐制成适于人或动物使用的任何剂型。本发明所述卡莫氟或其药学上可接受的盐在其药物组合物中的重量含量通常为0.1-99.0%。
所述的药学可接受的载体可为本领域常规的载体,所述的载体可以为任意合适的生理学或药学上可接受的药物辅料。所述的药物辅料为本领域常规的药物辅料,较佳地包括药学上可接受的赋形剂、填充剂或稀释剂等。更佳地,所述的药物组合物包括0.01~99.99%的上述蛋白质和/或上述的抗体药物偶联物,和0.01~99.99%的药用载体,所述百分比为占所述药物组合物的质量百分比。
本发明所述卡莫氟或其药学上可接受的盐或含其的药物组合物可以单位剂量形式给药,给药途径可为肠道或非肠道,如口服、静脉注射、肌肉注射、皮下注射、鼻腔、口腔粘膜、眼、肺和呼吸道、皮肤、阴道、直肠等。
给药剂型可以是液体剂型、固体剂型或半固体剂型。液体剂型可以是溶液剂(包括真溶液和胶体溶液)、乳剂(包括o/w型、w/o型和复乳)、混悬剂、注射剂(包括水针剂、粉针剂和输液)、滴眼剂、滴鼻剂、洗剂和搽剂等;固体剂型可以是片剂(包括普通片、肠溶片、含片、分散片、咀嚼片、泡腾片、口腔崩解片)、胶囊剂(包括硬胶囊、软胶囊、肠溶胶囊)、颗粒剂、散剂、微丸、滴丸、栓剂、膜剂、贴片、气(粉)雾剂、喷雾剂等;半固体剂型可以是软膏剂、凝胶剂、糊剂等。
本发明所述卡莫氟或其药学上可接受的盐可以制成普通制剂、也可以制成缓释制剂、控释制剂、靶向制剂及各种微粒给药系统。
术语“药学上可接受的”是指盐、溶剂、辅料等一般无毒、安全,并且适合于患者使用。所述的“患者”优选哺乳动物,更优选为人类。
术语“药学上可接受的盐”是指本发明所述卡莫氟与相对无毒的、药学上可接受的酸或碱制备得到的盐。当本发明的所述卡莫氟或其药学上可接受的盐中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的药学上可接受的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括但不限于:锂盐、钠盐、钾盐、钙盐、铝盐、镁盐、锌盐、铋盐、铵盐、二乙醇胺盐。当本发明的所述卡莫氟或其药学上可接受的盐中含有相对碱性的官能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的药学上可接受的酸与这类化合物的中性形式接触的方式获得酸加成盐。所述的药学上可接受的酸包括无机酸,所述无机酸包括但不限于:盐酸、氢溴酸、氢碘酸、硝酸、碳酸、磷酸、亚磷酸、硫酸等。所述的药学上可接受的酸包括有机酸,所述有机酸包括但不限于:乙酸、丙酸、草酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、水杨酸、酒石酸、甲磺酸、异烟酸、酸式柠檬酸、油酸、单宁酸、泛酸、酒石酸氢、抗坏血酸、龙胆酸、富马酸、葡糖酸、糖酸、甲酸、乙磺酸、双羟萘酸(即4,4’-亚甲基-双(3- 羟基-2-萘甲酸))、氨基酸(例如谷氨酸、精氨酸)等。当本发明的化合物中含有相对酸性和相对碱性的官能团时,可以被转换成碱加成盐或酸加成盐。具体可参见Berge et al., "Pharmaceutical Salts",Journal of PharmaceuticalScience 66:1-19(1977)、或、Handbook of Pharmaceutical Salts:Properties,Selection,and Use(P.Heinrich Stahl and Camille G. Wermuth,ed.,Wiley-VCH,2002)。
在符合本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:
本发明通过体外酶活实验发现卡莫氟可以很好地抑制冠状病毒中的主蛋白酶的活性,填补了现有技术缺乏治疗冠状病毒引发的疾病的不足。可对该化合物进行进一步研究、改造以进行应用。
附图说明
图1:卡莫氟对新型冠状病毒主蛋白酶的抑制活性;1:DMSO(阴性对照),2:化合物分子;3:阳性对照(N3抑制剂)。纵坐标单位为RFU(Relative Fluorescence Units;相对荧光的单位)。
图2:卡莫氟对新冠病毒主蛋白酶的酶活抑制曲线。
图3:卡莫氟在细胞水平上的抗病毒效果,数据通过qRT-PCR方法测得。
图4:卡莫氟在细胞水平上的抗病毒效果,数据通过免疫荧光法测得,以氯喹作为阳性对照。
图5:体外细胞毒性实验,测定细胞存活率。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
以下所用Vero E6细胞购自ATCC。
实施例1
从不同的化合物库中进行高通量筛选,成功筛选卡莫氟对新型冠状病毒主蛋白酶有较好的抑制效果。酶活实验条件具体为:
酶活实验荧光底物:MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2,此荧光底物的激发波长和发射波长分别为320nm和405nm。
酶活反应buffer为50mM Tris–HCl(pH 7.3),1mM EDTA;酶活反应温度:30℃。反应起始通过添加蛋白酶,蛋白酶反应终浓度为0.2μM,底物浓度为20μM,抑制剂(卡莫氟)浓度1.5μM。(Xue X,Yang H,Shen W,et al.Production of authentic SARS-CoV Mpro withenhanced activity:application as a novel tag-cleavage endopeptidase forprotein overproduction[J].Journal of molecular biology,2007,366(3):965-975.)。
所用阳性对照为N3抑制剂,已知其能够有效灭活冠状病毒主蛋白酶(杨海涛,谢卫青,Xiaoyu X,et al.Design of wide-spectrum inhibitors targeting coronavirusmain proteases[J]. 生命有机化学,2005,3(10):1742-1752.),结构式如下所示:
根据图1可知:卡莫氟的酶活实验曲线,明显区别于阴性对照,对冠状病毒主蛋白酶有明显抑制活性。
实施例2
酶活抑制曲线测定使用的荧光底物:MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2,此荧光底物的激发波长和发射波长分别为320nm和405nm。
酶活抑制曲线测定buffer为50mM Tris–HCl(pH 7.3),1mM EDTA;反应温度: 30℃。反应起始通过添加蛋白酶,蛋白酶反应终浓度为0.2μM,底物浓度为20μM,使用11个不同浓度的卡莫氟进行测量,测试结果显示IC50值为1.82μM(图2)(Jin Z,Du X,Xu Y,etal.Structure of Mpro from COVID-19virus and discovery of its inhibitors[J].Nature,2020,582(7811):1-9.)。
体外细胞抗病毒实验使用6个不同浓度的卡莫氟处理感染SARS-CoV-2的Vero E6细胞1小时,病毒MOI(multiplicity of infection)为0.05。然后去除病毒和药物和混合物,清洗后继续使用含不同浓度卡莫氟的培养基培养。经过24小时培养后取上清进行qRT-PCR分析,同时将细胞固定通过免疫荧光法检测细胞内N蛋白水平进一步确定实验结果。实验发现卡莫氟可防止新型冠状病毒感染引起的细胞病变,EC50值为24.3μM(图3、图 4),因此卡莫氟可用于治疗冠状病毒引发的相关疾病(Jin,Z.,Zhao,Y.,Sun,Y.et al. Structuralbasis for the inhibition of SARS-CoV-2main protease by antineoplastic drugcarmofur. Nat Struct Mol Biol 27,529–532(2020).)。
体外的细胞毒性实验使用8个不同浓度的卡莫氟处理Vero E6细胞。Vero E6细胞在 96孔板中悬浮培养。第二天,在培养基中加入不同浓度的卡莫氟。24小时后,使用细胞计数试剂盒-8(CCK8,Beyotime)测定存活细胞的相对数量。如图5所示,卡莫氟的CC50 值为133.37μM(Jin,Z.,Zhao,Y.,Sun,Y.et al.Structural basis for the inhibition ofSARS- CoV-2main protease by antineoplastic drug carmofur.Nat Struct Mol Biol27,529–532 (2020).)。
Claims (5)
1.卡莫氟或其药学上可接受的盐在制备治疗SARS-CoV-2引发的疾病的药物中的应用,所述卡莫氟或其药学上可接受的盐作为所述药物的唯一活性成分。
2.卡莫氟或其药学上可接受的盐作为唯一活性成分的组合物在制备抑制SARS-CoV-2的药物中的应用。
3.如权利要求2所述的应用,其特征在于,所述卡莫氟或其药学上可接受的盐以包含其的药物组合物的形式存在,所述的药物组合物还包含药学上可接受的载体。
4.如权利要求3所述的应用,其特征在于,所述的药学上可接受的载体为药学上可接受的药用辅料。
5.如权利要求2所述的应用,其特征在于,所述卡莫氟或其药学上可接受的盐以包含其的套装药盒的形式存在,所述套装药盒还包括治疗与SARS-CoV-2相关的疾病的药物和/或治疗其他病毒引起的疾病的药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211104669.6A CN115770246B (zh) | 2020-02-26 | 2021-02-26 | 卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010121688 | 2020-02-26 | ||
CN2020101216884 | 2020-02-26 | ||
CN202211104669.6A CN115770246B (zh) | 2020-02-26 | 2021-02-26 | 卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用 |
CN202110219570.XA CN113304131B (zh) | 2020-02-26 | 2021-02-26 | 多酚类物质在抗冠状病毒中的应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110219570.XA Division CN113304131B (zh) | 2020-02-26 | 2021-02-26 | 多酚类物质在抗冠状病毒中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115770246A CN115770246A (zh) | 2023-03-10 |
CN115770246B true CN115770246B (zh) | 2024-01-23 |
Family
ID=77370947
Family Applications (13)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211105211.2A Active CN115998718B (zh) | 2020-02-26 | 2021-02-26 | 紫草素在抗冠状病毒中的应用 |
CN202211107010.6A Active CN115252610B (zh) | 2020-02-26 | 2021-02-26 | 质子泵抑制剂在抗冠状病毒中的应用 |
CN202110219570.XA Active CN113304131B (zh) | 2020-02-26 | 2021-02-26 | 多酚类物质在抗冠状病毒中的应用 |
CN202211105198.0A Active CN115569133B (zh) | 2020-02-26 | 2021-02-26 | 甲异靛在抗冠状病毒中的应用 |
CN202211104686.XA Pending CN115645396A (zh) | 2020-02-26 | 2021-02-26 | 丙基-2-咪唑二硫醚在抗冠状病毒中的应用 |
CN202180016668.3A Pending CN115175673A (zh) | 2020-02-26 | 2021-02-26 | 双硫仑在抗冠状病毒中的应用 |
CN202211104682.1A Active CN115778943B (zh) | 2020-02-26 | 2021-02-26 | 秦皮素在抗冠状病毒中的应用 |
CN202211106171.3A Pending CN115645393A (zh) | 2020-02-26 | 2021-02-26 | 二氢杨梅素在抗冠状病毒中的应用 |
CN202211105155.2A Pending CN115569135A (zh) | 2020-02-26 | 2021-02-26 | 替徳格塞在抗冠状病毒中的应用 |
CN202211106165.8A Active CN115569196B (zh) | 2020-02-26 | 2021-02-26 | 多酚类物质在抗冠状病毒中的应用 |
CN202211105196.1A Active CN115671119B (zh) | 2020-02-26 | 2021-02-26 | 柯里拉京在抗冠状病毒中的应用 |
CN202211104684.0A Active CN115581692B (zh) | 2020-02-26 | 2021-02-26 | 苏木的活性成分在抗冠状病毒中的应用 |
CN202211104669.6A Active CN115770246B (zh) | 2020-02-26 | 2021-02-26 | 卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用 |
Family Applications Before (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211105211.2A Active CN115998718B (zh) | 2020-02-26 | 2021-02-26 | 紫草素在抗冠状病毒中的应用 |
CN202211107010.6A Active CN115252610B (zh) | 2020-02-26 | 2021-02-26 | 质子泵抑制剂在抗冠状病毒中的应用 |
CN202110219570.XA Active CN113304131B (zh) | 2020-02-26 | 2021-02-26 | 多酚类物质在抗冠状病毒中的应用 |
CN202211105198.0A Active CN115569133B (zh) | 2020-02-26 | 2021-02-26 | 甲异靛在抗冠状病毒中的应用 |
CN202211104686.XA Pending CN115645396A (zh) | 2020-02-26 | 2021-02-26 | 丙基-2-咪唑二硫醚在抗冠状病毒中的应用 |
CN202180016668.3A Pending CN115175673A (zh) | 2020-02-26 | 2021-02-26 | 双硫仑在抗冠状病毒中的应用 |
CN202211104682.1A Active CN115778943B (zh) | 2020-02-26 | 2021-02-26 | 秦皮素在抗冠状病毒中的应用 |
CN202211106171.3A Pending CN115645393A (zh) | 2020-02-26 | 2021-02-26 | 二氢杨梅素在抗冠状病毒中的应用 |
CN202211105155.2A Pending CN115569135A (zh) | 2020-02-26 | 2021-02-26 | 替徳格塞在抗冠状病毒中的应用 |
CN202211106165.8A Active CN115569196B (zh) | 2020-02-26 | 2021-02-26 | 多酚类物质在抗冠状病毒中的应用 |
CN202211105196.1A Active CN115671119B (zh) | 2020-02-26 | 2021-02-26 | 柯里拉京在抗冠状病毒中的应用 |
CN202211104684.0A Active CN115581692B (zh) | 2020-02-26 | 2021-02-26 | 苏木的活性成分在抗冠状病毒中的应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230293457A1 (zh) |
EP (1) | EP4115880A4 (zh) |
JP (1) | JP2023515227A (zh) |
KR (1) | KR20220146558A (zh) |
CN (13) | CN115998718B (zh) |
BR (1) | BR112022017060A2 (zh) |
WO (1) | WO2021170093A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210386695A1 (en) * | 2020-06-16 | 2021-12-16 | China Medical University | Use Of Disulfiram For Treating Infection Of SARS-COV-2 |
CN113648293B (zh) * | 2021-08-19 | 2022-07-05 | 山东达因海洋生物制药股份有限公司 | 对苯醌和/或对苯醌衍生物在制备抗新型冠状病毒药物中的应用 |
CN114668751A (zh) * | 2022-03-22 | 2022-06-28 | 天津国际生物医药联合研究院 | 双硫仑在抗人冠状病毒nl63感染中的应用 |
CN115089564A (zh) * | 2022-05-18 | 2022-09-23 | 南方科技大学 | 紫草素和左旋紫草素在制备抗冠状病毒药物中的应用 |
CN115025165A (zh) * | 2022-06-09 | 2022-09-09 | 南京农业大学 | 莓茶提取物在制备抗猪流行性腹泻病毒的药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108137563A (zh) * | 2015-08-18 | 2018-06-08 | 卡尔约药物治疗公司 | 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3511609A1 (de) * | 1985-03-29 | 1986-10-02 | Moon Chang Kiu Dr | Arzneimittel, dessen herstellung und verwendung |
AU781133B2 (en) * | 1999-02-26 | 2005-05-05 | Nicox S.A. | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use |
WO2003074000A2 (en) * | 2002-03-01 | 2003-09-12 | Omega Pharmaceutical, Inc. | Eleutherosides as adjuncts for vaccines and immune modulation |
US7897640B2 (en) * | 2003-02-21 | 2011-03-01 | Beijing Jbc Chinese Traditional Medicine Science And Technology Develop Co. Ltd | Method of treatment of virus infections using shikonin compounds |
US20050222258A1 (en) * | 2003-02-21 | 2005-10-06 | Feixin Wang | Pharmaceuticals comprising shikonins as active constituent |
CN1829736A (zh) * | 2003-04-10 | 2006-09-06 | 希龙公司 | 严重急性呼吸道综合征冠状病毒 |
CN1539426A (zh) * | 2003-04-23 | 2004-10-27 | 陈建操 | 治疗和预防sars疾病的药物 |
EP1628674A2 (en) * | 2003-05-06 | 2006-03-01 | Cytovia, Inc. | Protease inhibitors for coronaviruses and sars-cov and the use thereof |
CN1644199A (zh) * | 2003-05-30 | 2005-07-27 | 任启生 | 蛇葡萄素在制备广谱抗病毒药物中的用途 |
CN1237185C (zh) * | 2003-06-04 | 2006-01-18 | 中国科学院上海药物研究所 | Sars冠状病毒3cl蛋白酶三维结构模型与抗sars药物 |
CN1296041C (zh) * | 2003-10-20 | 2007-01-24 | 北京大学 | 抑制sars冠状病毒感染的中药有效成分及其生物活性测定方法 |
WO2006024545A1 (en) * | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
CN100363346C (zh) * | 2004-10-22 | 2008-01-23 | 清华大学 | 冠状病毒主蛋白酶的小分子抑制剂、制备方法及其应用 |
US20060189543A1 (en) * | 2005-02-23 | 2006-08-24 | Rosenbloom Richard A | Compositions and methods for the treatment of leukemia |
GB0519169D0 (en) * | 2005-09-21 | 2005-10-26 | Leuven K U Res & Dev | Novel anti-viral strategy |
US20080057111A1 (en) * | 2006-08-29 | 2008-03-06 | Lixian Jiang | Herbal composition for flu prevention and treatment |
SG191445A1 (en) * | 2006-12-22 | 2013-07-31 | Univ Johns Hopkins | Anti-cholesterolemic compounds and methods of use |
GB0809898D0 (en) * | 2008-06-02 | 2008-07-09 | Univ Ghent | Methods and compositions in the treatment of coronaviruses |
TWI375671B (en) * | 2010-03-01 | 2012-11-01 | Univ China Medical | Pharmaceutical compositions containing brazilin for inhibiting expression of cytokines of t helper cell type ii and/or inhibiting expression of chemokines and uses of the same |
US20110268722A1 (en) * | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
US20130203715A1 (en) * | 2010-07-20 | 2013-08-08 | Pulmatrix, Inc. | Use of trp channel agonists to treat infections |
KR20130031551A (ko) * | 2011-09-21 | 2013-03-29 | 동국대학교 산학협력단 | 사스 코로나바이러스의 활성을 억제하는 플라보노이드, 약학적으로 허용가능한 유도체 및 염, 이를 함유하는 사스 치료 또는 예방용 조성물 및 건강기능식품 |
CN103301097A (zh) * | 2012-03-14 | 2013-09-18 | 上海市肿瘤研究所 | 双硫仑在制备抗肝硬化或抗肝纤维化药物中的应用 |
CA2859099C (en) * | 2013-08-13 | 2022-01-11 | Natreon, Inc. | Terminalia chebula and terminalia bellerica extracts for inhibition of xanthine oxidase |
CN106794175B (zh) * | 2014-06-12 | 2020-06-09 | 西达-赛奈医疗中心 | 用于治疗癌症的组合物 |
WO2016090362A1 (en) * | 2014-12-05 | 2016-06-09 | Vanderbilt University | Identification of cellular antimicrobial drug targets through interactome analysis |
WO2016172528A1 (en) * | 2015-04-23 | 2016-10-27 | Inhibikase Therapeutics, Inc. | Compositions and methods for inhibiting kinases |
CN115300640A (zh) * | 2015-08-10 | 2022-11-08 | 杭州多禧生物科技有限公司 | 新型连接体及其用于药物和生物分子的特异性偶联 |
GB201519643D0 (en) | 2015-11-06 | 2015-12-23 | Univ Wolverhampton | Disulfiram formulation |
CN105687226B (zh) * | 2016-01-27 | 2018-04-13 | 中国人民解放军疾病预防控制所 | 一种用于抑制冠状病毒感染的制剂 |
CN107022008B (zh) * | 2016-01-30 | 2021-04-23 | 山西锦波生物医药股份有限公司 | 广谱地抑制人类冠状病毒感染的多肽及其应用 |
CA3019841A1 (en) * | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
CN106187933B (zh) * | 2016-06-27 | 2018-09-04 | 南开大学 | 不对称芳香二硫醚类化合物及其在制备抗sars冠状病毒感染药物中的应用 |
CN106176728B (zh) * | 2016-07-07 | 2018-10-09 | 中国科学院微生物研究所 | 不对称二硫醚类化合物在抗sars冠状病毒感染中的应用 |
US20200247758A1 (en) * | 2017-01-17 | 2020-08-06 | Michael David FORREST | Therapeutic Inhibitors of the Reverse Mode of ATP Synthase |
CA3058407A1 (en) * | 2017-03-29 | 2018-10-04 | Phosphorex, Inc. | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same |
CN108478562B (zh) * | 2018-05-04 | 2022-04-01 | 中国疾病预防控制中心病毒病预防控制所 | 麦考酚酸及其衍生物吗替麦考酚酯在制备广谱抗冠状病毒药物中的应用 |
CN111387194A (zh) * | 2020-02-24 | 2020-07-10 | 云南农业大学 | 一类高效特异性防治新型冠状病毒感染的化合物及其应用 |
GB202007377D0 (en) * | 2020-05-19 | 2020-07-01 | Univ Of Wolverhampton | Composition |
-
2021
- 2021-02-26 US US17/801,689 patent/US20230293457A1/en active Pending
- 2021-02-26 CN CN202211105211.2A patent/CN115998718B/zh active Active
- 2021-02-26 CN CN202211107010.6A patent/CN115252610B/zh active Active
- 2021-02-26 CN CN202110219570.XA patent/CN113304131B/zh active Active
- 2021-02-26 JP JP2022551788A patent/JP2023515227A/ja active Pending
- 2021-02-26 CN CN202211105198.0A patent/CN115569133B/zh active Active
- 2021-02-26 CN CN202211104686.XA patent/CN115645396A/zh active Pending
- 2021-02-26 EP EP21760398.4A patent/EP4115880A4/en active Pending
- 2021-02-26 CN CN202180016668.3A patent/CN115175673A/zh active Pending
- 2021-02-26 BR BR112022017060A patent/BR112022017060A2/pt unknown
- 2021-02-26 CN CN202211104682.1A patent/CN115778943B/zh active Active
- 2021-02-26 CN CN202211106171.3A patent/CN115645393A/zh active Pending
- 2021-02-26 CN CN202211105155.2A patent/CN115569135A/zh active Pending
- 2021-02-26 CN CN202211106165.8A patent/CN115569196B/zh active Active
- 2021-02-26 CN CN202211105196.1A patent/CN115671119B/zh active Active
- 2021-02-26 WO PCT/CN2021/078185 patent/WO2021170093A1/zh unknown
- 2021-02-26 CN CN202211104684.0A patent/CN115581692B/zh active Active
- 2021-02-26 CN CN202211104669.6A patent/CN115770246B/zh active Active
- 2021-02-26 KR KR1020227033090A patent/KR20220146558A/ko unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108137563A (zh) * | 2015-08-18 | 2018-06-08 | 卡尔约药物治疗公司 | 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
Non-Patent Citations (2)
Title |
---|
Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic dru;Jin Z, Zhao Y, Sun Y, et al;bioRxiv;全文 * |
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofu;Jin Z, Zhao Y, Sun Y, et al.;Nature structural & molecular biology;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN115770246A (zh) | 2023-03-10 |
CN115569133B (zh) | 2024-04-26 |
WO2021170093A1 (zh) | 2021-09-02 |
CN115175673A (zh) | 2022-10-11 |
CN115581692A (zh) | 2023-01-10 |
CN115252610A (zh) | 2022-11-01 |
CN115569196B (zh) | 2024-06-18 |
CN115569135A (zh) | 2023-01-06 |
KR20220146558A (ko) | 2022-11-01 |
BR112022017060A2 (pt) | 2022-11-16 |
CN115581692B (zh) | 2023-10-17 |
EP4115880A4 (en) | 2024-04-10 |
CN115778943A (zh) | 2023-03-14 |
CN115671119A (zh) | 2023-02-03 |
CN113304131A (zh) | 2021-08-27 |
CN115645396A (zh) | 2023-01-31 |
CN115569196A (zh) | 2023-01-06 |
CN115569133A (zh) | 2023-01-06 |
EP4115880A1 (en) | 2023-01-11 |
CN115998718B (zh) | 2023-12-12 |
CN115778943B (zh) | 2023-11-10 |
CN115645393A (zh) | 2023-01-31 |
US20230293457A1 (en) | 2023-09-21 |
CN113304131B (zh) | 2022-10-18 |
CN115252610B (zh) | 2024-03-26 |
CN115671119B (zh) | 2023-11-10 |
CN115998718A (zh) | 2023-04-25 |
JP2023515227A (ja) | 2023-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115770246B (zh) | 卡莫氟或其药学上可接受的盐在抗冠状病毒中的应用 | |
CN113289018B (zh) | 金诺芬等老药及其组合物在抗单正链rna病毒中的应用 | |
JP2024003097A (ja) | コロナウイルス感染の治療におけるファビピラビルの使用 | |
CN113679726A (zh) | 丹参提取物和醌类化合物在抗冠状病毒中的应用 | |
CN113350330B (zh) | 杨梅素类化合物在制备防治新冠肺炎药物中的应用 | |
US20210369696A1 (en) | Use of an N-substituted pyridyl benzisoselazolone compound | |
US20230302019A1 (en) | Compound for treating and/or preventing diseases caused by coronavirus and use thereof | |
CN113262224A (zh) | 奈非那韦在制备防治新冠肺炎药物中的应用 | |
KR20100066142A (ko) | 3,5-디아릴-4,5-디히드로 피라졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 피코르나바이러스 및 코로나바이러스에 의해 유발되는 질환의 예방 또는 치료용 조성물 | |
CN115475154B (zh) | 棉酚及其衍生类似物在制备抗新型冠状病毒及其类似rna病毒产品的应用 | |
WO2022166933A1 (zh) | 化合物在抗冠状病毒中的应用 | |
WO2021164672A1 (zh) | 抗rna病毒药物及其应用 | |
CN116687932B (zh) | ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯的医药用途 | |
CN116003508A (zh) | 一种含氰基的硒代丁内酰胺化合物及其制备方法和用途 | |
EP3960173A1 (en) | Enterovirus inhibitor | |
CN115813893A (zh) | 萘基骨架类化合物在制备冠状病毒3cl蛋白酶抑制剂中的应用 | |
CN115991700A (zh) | 一种含硒的三嗪衍生物及其制备方法和用途 | |
CN118320079A (zh) | 卟啉类化合物或其药学上可接受的盐在制备抗猪病毒药物中的应用 | |
KR20220134489A (ko) | 폴리포스페이트를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 | |
CN110123802A (zh) | 以乙酰紫草素为代表的几种中药单体在抗肠道病毒d68型感染中的应用 | |
CDC et al. | A Viral Biorealm page on the genus Coronavirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |